OncoAlvo.: Technological Innovation Optimised for the Personalisation of Oncology Therapy (Q2866833): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: co-financing rate (P837): 74.63 percentage) |
(Changed an Item: Import item from Portugal) |
||||||||||
Property / budget | Property / budget | ||||||||||
| 467,815.86 Euro
| ||||||||||
Property / EU contribution | Property / EU contribution | ||||||||||
| 349,140.37 Euro
| ||||||||||
Property / priority axis | |||||||||||
Property / priority axis: Research, Development and Innovation (DIIAS) / rank | |||||||||||
Normal rank | |||||||||||
Property / co-financing rate | |||||||||||
74.63 percent
| |||||||||||
Property / co-financing rate: 74.63 percent / rank | |||||||||||
Normal rank |
Revision as of 22:24, 8 November 2022
Project Q2866833 in Portugal
Language | Label | Description | Also known as |
---|---|---|---|
English | OncoAlvo.: Technological Innovation Optimised for the Personalisation of Oncology Therapy |
Project Q2866833 in Portugal |
Statements
349,140.37 Euro
0 references
467,815.86 Euro
0 references
74.63 percent
0 references
1 March 2016
0 references
1 March 2018
0 references
HEARTGENETICS GENETICS AND BIOTECHNOLOGY, S.A.
0 references
Cantanhede
0 references
Identifiers
CENTRO-01-0247-FEDER-010500
0 references